An AbbVie schizophrenia drug acquired as a part of a multibillion-dollar deal has failed two interim trials, dealing a setback to the corporate's plans to compete with a Bristol Myers Squibb drug that was not too long ago authorised for schizophrenia and is predicted to be a blockbuster vendor for a number of psychiatric indications. The preliminary outcomes introduced Monday […]